Price to Book Value Chart

View Price to Book Value for XTLB.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Price to Book Value Chart
Start Trial

Historical Price to Book Value Data

View and export this data back to 2009. Start Trial.
Date Value
August 24, 2026 1.064
August 21, 2026 1.127
August 20, 2026 1.120
August 19, 2026 1.208
August 18, 2026 1.310
August 17, 2026 1.054
August 14, 2026 1.129
August 13, 2026 1.135
August 12, 2026 1.091
August 11, 2026 1.074
August 10, 2026 1.164
August 07, 2026 1.192
August 06, 2026 1.164
August 05, 2026 1.156
August 04, 2026 1.168
August 03, 2026 1.160
July 31, 2026 1.143
July 30, 2026 1.156
July 29, 2026 1.200
July 28, 2026 1.200
July 27, 2026 1.168
July 24, 2026 1.192
July 23, 2026 1.176
July 22, 2026 1.184
July 21, 2026 1.184
Date Value
July 20, 2026 1.172
July 17, 2026 1.151
July 16, 2026 1.147
July 15, 2026 1.188
July 14, 2026 1.200
July 13, 2026 1.168
July 10, 2026 1.180
July 09, 2026 1.172
July 08, 2026 1.176
July 07, 2026 1.208
July 06, 2026 1.273
July 02, 2026 1.095
July 01, 2026 1.010
June 30, 2026 1.107
June 29, 2026 0.9568
June 26, 2026 0.9568
June 25, 2026 1.040
June 24, 2026 1.130
June 23, 2026 1.131
June 22, 2026 1.095
June 18, 2026 1.030
June 17, 2026 0.9811
June 16, 2026 0.9649
June 15, 2026 0.9325
June 12, 2026 0.8636

Price to Book Ratio Definition

Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.

Read full definition.

Price to Book Value Range, Past 5 Years

View Price to Book Value Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Price to Book Value Benchmarks

View Price to Book Value Benchmarks
Start Trial
BioLineRx Ltd. 0.7829
Kamada Ltd. 1.804
Can-Fite BioPharma Ltd. 2.432
Galmed Pharmaceuticals Ltd. 0.2396
Revium Recovery, Inc. --

Price to Book Value Related Metrics

Price 2.625
Market Cap 6.210M